Contrast-enhanced MRI for breast cancer screening by Mann, R.M. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/208984
 
 
 
Please be advised that this information was generated on 2020-09-09 and may be subject to
change.
REVIEW ARTICLE
Contrast-Enhanced MRI for Breast
Cancer Screening
Ritse M. Mann, MD, PhD,1,2* Christiane K. Kuhl, MD, PhD,3 and Linda Moy, MD4
Multiple studies in the first decade of the 21st century have established contrast-enhanced breast MRI as a screening
modality for women with a hereditary or familial increased risk for the development of breast cancer. In recent studies,
in women with various risk profiles, the sensitivity ranges between 81% and 100%, which is approximately twice as high
as the sensitivity of mammography. The specificity increases in follow-up rounds to around 97%, with positive predictive
values for biopsy in the same range as for mammography. MRI preferentially detects the more aggressive/invasive types
of breast cancer, but has a higher sensitivity than mammography for any type of cancer. This performance implies that in
women screened with breast MRI, all other examinations must be regarded as supplemental. Mammography may yield
~5% additional cancers, mostly ductal carcinoma in situ, while slightly decreasing specificity and increasing the costs.
Ultrasound has no supplemental value when MRI is used. Evidence is mounting that in other groups of women the per-
formance of MRI is likewise superior to more conventional screening techniques. Particularly in women with a personal
history of breast cancer, the gain seems to be high, but also in women with a biopsy history of lobular carcinoma in situ
and even women at average risk, similar results are reported. Initial outcome studies show that breast MRI detects can-
cer earlier, which induces a stage-shift increasing the survival benefit of screening. Cost-effectiveness is still an issue,
particularly for women at lower risk. Since costs of the MRI scan itself are a driving factor, efforts to reduce these costs
are essential. The use of abbreviated MRI protocols may enable more widespread use of breast MRI for screening.
Level of Evidence: 1
Technical Efficacy: Stage 5
J. MAGN. RESON. IMAGING 2019;50:377–390.
Screening for Breast Cancer
Mammography
SCREENING FOR BREAST CANCER is mostly mam-mography-based. The basic concept is that detection of
cancer before symptoms occur allows for better treatment,
and therefore reduced breast cancer-related morbidity and
mortality. In essence, the detection and treatment of ductal
carcinoma in situ (DCIS), especially of high-grade DCIS, can
even be regarded as a form of primary prevention of breast
cancer development. Several meta-analyses of randomized
controlled trials on mammography screening showed that this
concept works, with a reported mortality reduction of ~20%
in women invited to screening,1 and a much higher mortality
reduction in women actually undergoing screening.2
Unfortunately, mammography fails to detect a significant
amount of cancers before the symptomatic phase that conse-
quently present as interval carcinomas between screening rounds.
Particularly in women with a large relative fraction of fibrogland-
ular tissue, ie, with "dense" breasts, up to 50% of cancers is
detected between screening rounds.3,4
Women at an increased risk for the development of breast
cancer are usually prone to develop breast cancer at a much
younger age, and are consequently screened from a younger
age.5,6 As a result, the fraction of women in this population with
extremely dense breasts is high. In addition, imaging characteris-
tics of cancers developing in women at very high risk are less
specific and may resemble benign lesions.7,8 Consequently,
mammographic screening in women at increased risk has sub-
stantially lower performance than in the average population.
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After the initial realization that contrast-enhanced breast
magnetic resonance imaging (MRI) has a very high sensitiv-
ity for the detection of breast cancer,9,10 it was rapidly tested
as a supplementary screening tool. The high sensitivity is
based on the fact that no breast cancer can grow beyond
2 mm in size without creating new blood vessels that pro-
vide sufficient nutrients for the tumor to grow.11 This neo-
vascularization results in creation of vessels that are leaky.
Gadolinium-based contrast agents, which are relatively large
molecules, can easily extravasate from such vessels, and
therefore rapidly accumulate in the breast cancer stroma.12
Their paramagnetic properties shorten the T1 time in the
surrounding tissue, and therefore increase the local signal on
T1-based sequences. A basic breast MRI protocol consists
of one precontrast T1-weighted acquisition and several
T1-weighted acquisitions after contrast administration in
order to document the kinetic behavior of contrast accumu-
lation in a lesion, since the leakiness of the vessels in cancer
also leads to rapid washout of the contrast agent. Often a
T2-weighted acquisition is also obtained.
13,14
Following a single-center study that showed the potential
of MRI as a screening tool,15–17 several large-scale multicenter
trials were conducted to assess the value of MRI as a supple-
mentary screening tool. Inclusion criteria varied, but always
included women with germline mutations in the BRCA1 and
BRCA2 genes, in many instances supplemented with women
at increased risk based on familial predisposition.18–22 Albeit in
some of the initial studies the sensitivity of breast MRI was
lower than expected—71% in the Dutch Magnetic Resonance
Imaging screening study (MRISC),18 and 77% in the British
Magnetic Resonance Imaging in Breast Screening study
(MARIBS)19—MRI almost doubled the sensitivity of mam-
mography in all studies. In meta-analysis, a sensitivity of 77%
for MRI was reported (compared with 39% for mammogra-
phy), with a specificity of 86% (compared with 95% for mam-
mography).23 The relatively low sensitivity of the initial studies
is likely due to a, at that time, still immature technique in
combination with the absence of clear interpretation guidelines,
especially for nonmass lesions.
In later studies, such as the German EVA trial and the
High Breast Cancer Risk Italian 1 Study (HIBCRIT-1), the
sensitivity was over 90%.24,25 Recent large series presenting a
realistic overview of the current performance of breast MRI
for screening are listed in Table 1. Sensitivity of MRI alone
ranges between 75.2% and 100%, and is generally over 80%;
specificity ranges between 83% and 98.4%. In the studies
that report on prevalent and incident rounds, the specificity
of MRI alone climbs from ~90–97%, which implies that the
lower specificity of MRI is mainly a first-round effect. The
range of reported positive predictive values for biopsy runs
from 11–40%, which is similar to what is reported for mam-
mography. A large fraction of false-positive findings in breast
MRI (40%) is due to the detection of enhancing high-risk
lesions, which may still be relevant for determination of the
screening regimen.26 In general, true interval cancers are rare
in women screened with MRI, occurring mainly in BRCA
mutation carriers (eg, 11 of 16 interval cancers in the study
by Vreemann et al27).
Supplemental Screening Techniques
Based on the results of the screening studies listed in Table 1,
together documenting 56,801 screening examinations per-
formed in 29,172 women, it follows that for any woman
screened with breast MRI any other screening modality
should be regarded as a supplemental test with only a minor
contribution to early cancer detection.
Mammography
The most commonly used supplemental test is without
doubt mammography, as the postulate has long been
reversed (MRI was regarded as a supplemental test to mam-
mography). It is important to realize that this is no longer
true, even when studies are still presenting MRI as a supple-
mental test.34,36 The incremental cancer detection with
mammography ranges from 0–19.4%.22–32 However, the
study by Sung et al reports on MRI and mammography
examinations that were not simultaneously obtained and
should therefore likely be disregarded in this sense.31
Hence, the added sensitivity with mammography is around
5%, ranging from 0–8.6%. This comes at a decrease in
specificity ranging between 0.4–2%. While the latter
appears modest, it should be realized that even in high-risk
screening no more than 2% of the examinations are posi-
tive, and therefore a modest reduction in specificity affects
many women. Also, other side effects of supplemental mam-
mography, such as the need for compression, the use of ion-
izing radiation, and incremental costs need to be taken into
account.
Sung et al show that the types of tumors detected by
MRI and mammography are different, based on a very large
cohort of 18,064 screening MRI examinations and 26,866
mammographic examinations; the sensitivity of mammography
reduces for more aggressive/invasive types of cancers, whereas
the sensitivity of MRI increases,31 which is corroborated by
several other studies.37,38 Consequently, the gain of mammog-
raphy is mostly in the detection of DCIS, even though the sen-
sitivity of MRI for any grade of DCIS is higher than that of
mammography.31,37 Phi et al conducted a meta-analysis of the
earlier studies to determine the impact of mammography in
BRCA mutation carriers.39 In BRCA1 mutation carriers the
incremental cancer detection was 3.9%, whereas in BRCA2
mutation carriers the incremental detection was 12.6%. Dis-
turbingly, most incremental detections with mammography
only were done in the age group below 40 years (9.3% for
BRCA1 and 34.5% for BRCA2). They reported a number
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needed to screen of 717 for BRCA1 and 231 for BRCA2 to
detect an additional cancer after the first round. However, the
relatively low sensitivity of MRI in the included studies, partic-
ularly for DCIS, should be taken into account when interpret-
ing these data. Recent results on the sensitivity of MRI for
DCIS are much better, and, thus, the added value of mam-
mography is lower. In agreement with this, Obdeijn et al
reported on more recent data only a 2% incremental cancer
detection rate (CDR) in BRCA1 mutation carriers, two cases
of DCIS in women over 50.40 In a subsequent modeling study
they noted that mammography under 40 had no, or even a
negative effect, in this population.41 Narayan et al report a 0%
increase in cancer detection by adding mammography in
women below 40 with various risk factors.42 In a similar, but
much larger, mixed cohort, Vreemann et al reported 13/125
cancers to be solely detected by mammography, including eight
cases of DCIS.43 However, they reported no supplemental
detection in BRCA mutation carriers below the age of 50, and
overall 77% of additional detections in women over 50, leading
to a number of mammography screens needed to detect an
additional cancer in women younger than 50 of 1427.
Ultrasound
Since ultrasound is readily available, and has been shown to
be a useful supplemental screening tool in women with mam-
mographically dense breasts,44,45 the use of ultrasound as a
supplemental screening technique, usually on top of the com-
bination of MRI and mammography, has been evaluated.
This has been considered particularly for BRCA1 mutation
carriers, where, due to the particularly fast growth rates of
BRCA1-associated breast cancers, the "lead time" is particu-
larly short, such that in these women, interval cancer rates
can still be relatively high (11–25%).46 Table 2 lists the stud-
ies that performed such triple modality screening.
In none of the studies listed in Table 2, totaling 7696
screens in 3629 women, ultrasound contributed to cancer
detection at the screening rounds, while the yield of MRI in
an incident round after negative mammography and ultra-
sound still amounts to cancer detection in 14.7/1000
screens.44 Only in the study by Bosse et al were three cancers
detected in the 6-month interval.47 In the study by van Zelst
et al, two cancers were in retrospect visible at the 6-month
interval, but missed due to their benign appearance.48 The
addition of ultrasound to MRI and mammography leads to a
reduction of specificity of between 0% and 5.5%.
Outcome Effects
Since none of the initial MRI studies were randomized, direct
assessment of the effects of MRI screening on breast cancer-
specific survival is precluded. Rather, the studies used the
existing evidence that early detection improves outcomes
from the mammography screening trials as an argument for
the efficacy of MRI screening. Considering the fact that
several studies have shown that MRI preferentially detects the
more aggressive subtypes of breast cancer, this assumption
seems more than justified.31,37,38
Compared with nonrandomized control groups, several
studies showed that the fraction of minimal cancers (invasive
<1 cm) is much higher in women screened with MRI than in
women screened with mammography.46,49–51 Likewise, the
fraction of women with positive axillary lymph nodes is much
lower. Saadatmand et al reported improved metastasis-free
survival with a hazard ratio of 0.4 for patients who partici-
pated in the MRISC trial.52 Evans et al reported a signifi-
cantly higher overall survival of 95.3% in women at very high
risk participating in an MRI-based screening program com-
pared with 73.7% for equally high-risk women who did
not.51 According to Heijnsdijk et al, who combined the data
of several of the initial studies, the added mortality reduction
for a combined regimen is between 3% and 20%, and only
slightly lower for MRI screening alone.46 Still, Moller et al
report a 10-year survival of only 69% for BRCA1 mutation
carriers participating in an MRI-based screening program,
which points to the still much worse outcome in this specific
population.53 Podo et al, however, showed that the 5-year
overall survival difference between triple-negative breast can-
cers and less aggressive subtypes was relatively small
(86%  9% for TNBCs vs. 93%  5% for others) in
patients who participated in the HIBCRIT-1 trial.54
Current Indications for MRI Screening
The largely improved detection of early breast cancer shown
in the early studies is the basis for the widely adopted recom-
mendations of the American Cancer Society (ACS).55 They
advise MRI screening for all women with a lifetime risk for
the development of breast cancer of 20–25% or higher based
on family history or genetic predisposition. Based on expert
opinion, these recommendations also include women with a
history of radiation to the chest at a young age, and women
with p53 and PTEN mutation, which were underrepresented
in the original cohorts, but for whom the relative risk of
developing breast cancer is likewise high (roughly 6–8 times
the population risk).
These recommendations still form the basis for most
national and international guidelines. Unfortunately, due to
the fact that for many women the presence of genetic risk fac-
tors is unknown, and the fact that many facilities do not have
breast MRI available, there is a large fraction of eligible
women that is not screened according to these standards. In
part, this may also be due to inadequate patient information
about the benefits of MRI. Wernli et al reported that by
2009 29% of eligible women were screened with MRI.56
Miles et al showed that in 2012 43.9% of women with famil-
ial risk visited a clinic with MRI facilities for screening. How-
ever, only 6.6% were screened with MRI within 2 years from
380 Volume 50, No. 2
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a mammogram.57 Stout et al reported that only 48.4% of
women with known genetic mutations underwent MRI
screening.58
Developing Indications for Breast MRI
Screening
The ACS also defined patient categories where evidence was
insufficient to recommend for or against screening. These
include women with a lifetime risk of between 15% and 20%
(as these women were only included in the MRISC trial),
women with biopsy results of an atypical epithelial prolifera-
tion (lobular carcinoma in situ [LCIS], atypical lobular hyper-
plasia [ALH], atypical ductal hyperplasia [ADH]), women
with a personal history of breast cancer, and women with het-
erogeneously or extremely dense breasts on mammography.
Based on expert opinion, screening of women at average risk
(lifetime risk <15%) with MRI was not advised by the ACS.
Currently, however, evidence for the use of MRI screening in
these subgroups is mounting.
Hereditary and Familial Risk
Genetic testing has become more extensive in recent years;
women suspected of hereditary cancer are subjected to panel
tests that include other susceptibility genes such as PALB2,
STK11, CDH1, ATM, and CHECK2 that account for rela-
tive risks from 2.5–3 for lower-risk alterations such as
CHECK2 and ATM to 4–6 for the others.59,60 Local guide-
lines are rapidly changing to also include these mutations as
an indication for MRI screening. It should be noted that
women with a family history of breast cancer and such a
mutation are in general at higher risk than women in whom
the mutation was found accidentally.61,62 In the absence of a
genetic mutation, the risk for women with a family history of
breast cancer is somewhat lower. Consequently, the use of
MRI in women with only a family history of breast cancer is
changing somewhat.
Personal History of Breast Cancer
Women with a personal history of breast cancer (PHBC) are
at a substantially increased risk for the development of a sec-
ond breast cancer. Even though local recurrence rates are
nowadays relatively low, cumulative incidence of second
breast cancers may amount to 5.4% in 5 years.63 Schacht et al
reported a relative risk compared with women with a positive
family history of 1.4.64 The sensitivity of mammography for
early detection of second breast cancers is dismal due to post-
operative changes, including scar formation and dystrophic
calcifications. This implies that classically, most local recur-
rences are detected by palpation. However, it was shown that
earlier detection of second cancers, both in the ipsilateral and
contralateral breast, improves relative overall survival, espe-
cially in younger patients.65–67 Consequently, there is a clear
incentive for earlier detection of second cancers in women
with a personal history of breast cancer. In recent years many
studies evaluated the value of breast MRI for this purpose,
with remarkably concordant results, which are listed in
Table 3.
It should be noted that all but one of the 12 studies
listed in Table 3 are retrospective in nature, which implies
that even without formal recommendations for postoperative
screening with breast MRI, the technique is widely practiced.
Still, it also implies a patient selection, which favors young
patients, patients with very dense breasts, patients in whom
the initial cancer was mammographically occult, and patients
who also have a positive family history for breast cancer.
Therefore, the results may not be applicable to all women
with a personal history of breast cancer. In the evaluated stud-
ies, MRI sensitivity ranged from 80–100%, whereas mam-
mography sensitivity ranged from 0–53% (Table 3).
Specificities for MRI screening in this population are rela-
tively high (albeit still somewhat lower than for mammogra-
phy). However, in women with a personal history of breast
cancer breast imaging reporting and data system (BI-RADS)
3 evaluations, ie, likely benign findings with less than 2% risk
of being malignant, are rather common.36,69,72 In the early
phase after surgery this may be due to radiotherapy, causing
some focal residual enhancement in the breast that requires
follow-up imaging.77 This enhancement reduces over time.
Specificity is substantially higher in follow-up rounds than in
first-round examinations. Cho et al also evaluated the combi-
nation of mammography and ultrasound for this indication,
showing that in their population (Asian, which is relevant
due to the higher average breast density and lower cancer fre-
quency in these women compared with European or Ameri-
can women78,79) approximately half of the cancers detected
by MRI could also be found by ultrasound.36 Ultrasound did
not aid in cancer detection when MRI was used.
Atypical Epithelial Proliferations
Women with atypical epithelial proliferation such as atypical
ductal hyperplasia, atypical lobular hyperplasia, and lobular
carcinoma in situ have a relative risk for the development of
breast cancer of 3–10 times that of the general popula-
tion.80,81 Since the risk is on a par with other MRI screening
indications, several small-scale studies have been performed.
Sung et al detected cancer in 14 patients initially diagnosed
with LCIS after 840 screening rounds (MRI + Mx). Sensitiv-
ity was 71% for MRI and 36% for mammography; with no
overlap between MRI- and mammography-detected cases.82
The overall biopsy rate was 10.2% (7.1% due to MRI, 3.1%
due to Mx). In a similar screening study, Friedlander et al
reported the detection of five cancers in 307 screening stud-
ies, at a likewise relatively high biopsy rate (8,8%).83 Still,
cancer detection is strikingly similar between the studies
(1.6%), and the positive predictive values of biopsy are in the
range of normal findings. In addition, both studies report a
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high rate of additional high-risk lesions at biopsy (35 and
25.9%, respectively). However, in a study directly comparing
women with LCIS screened with MRI to women screened
only with mammography, King et al confirmed the high inci-
dence of cancer (13% in 5 years), but did not report a differ-
ence in overall CDR or eventual tumor stage between the
cohorts.84 Consequently, the benefit of MR screening in
women diagnosed with LCIS is not entirely sure, but likely
present. Some smaller studies also evaluated MRI screening in
other atypical hyperplasias, with CDRs between 0% and
1.5%85,86; however, for these types of lesions the evidence for
or against breast MRI screening is scarce.
Extremely Dense Breasts
Women with extremely dense breast tissue according to clinical
BI-RADS evaluation have a relative risk for the development of
breast cancer that is about 2.3 times higher than that of
women with scattered fibroglandular density.87 Moreover, their
risk of presenting with an interval cancer is about 5.6 times
higher,88 which is the major reason for the strong call for sup-
plemental screening techniques for these women. Since their
personal risk is in the same area as for women with a positive
family history, the use of breast MRI seems logical, albeit ultra-
sound is currently more commonly used. In two overlapping
studies using MRI, Chen et al reported additional cancer
detection in respectively 14 of 356 and 16 of 478 women with
a negative mammography.89,90 However, the exceptionally
high CDR in these studies (3.6%) seems to point to the pres-
ence of other risk factors as well, even though in the latter
study patients with a positive family history were excluded. To
determine the actual value of MRI screening in women with
extremely dense breasts, the results of the Dutch DENSE trial,
that randomizes women between MRI screening and no MRI
screening, and the ECOG-ACRIN 1141, that compares cancer
detection with an abbreviated MRI protocol to digital breast
tomosynthesis, need to be awaited.91,92 These results are
expected in the first half of 2019.
Women at Average Risk
The success of mammographic screening in the reduction of
breast cancer mortality is mostly due to the induction of a
stage-shift of the detected breast cancers. After implementa-
tion of screening, the fraction of cancers smaller than 2 cm
increased from 36–68%.93 Still, most tumors are detected
FIGURE 1: Typical finding of an MRI-detected breast cancer (arrow). In this case a 9 mm grade 2 invasive ductal carcinoma in a
46-year-old women screened because of familial risk. As with most cancers, this tumor is clearly evident on the maximum intensity
projection (MIP) image shown (A), which was created from subtraction images of regular high-resolution T1-weighted acquisitions
obtained prior to and 90 seconds after contrast injection. Ultrafast examinations may be used to differentiate the cancer from the
somewhat nodular parenchymal background enhancement. (B) MIP generated from the ultrafast series (8.6 sec after enhancement
of the descending aorta) is provided, showing that the lesion stands out from the other enhancing foci. (C) The corresponding
relative enhancement vs. time curve is given (type 2, plateau).
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with mammography when they are between 1 and 2 cm in
size, whereas the mean size of MRI-detected cancers is about
0.8 mm24,31,93 (Fig. 1). According to Lee et al, 69% of MRI-
detected cancers is smaller than 1 cm.35 For such small tumor
sizes, Welch et al reported overall survival estimates that
exceed the population average.93 Consequently, MRI has the
potential to further downstage the average cancer by earlier
detection and improve breast cancer-specific survival. Kuhl
et al reported detection of 22.6 additional cancers per 1000
screens in women at average risk with negative mammogra-
phy and ultrasound examinations in a prevalent round. In
subsequent incident rounds, the CDR with MRI dropped to
6.9 per 1000, supporting the hypothesis of a stage shift.
Importantly, this effect was equally present in all breast den-
sity categories,34 which seems to point to earlier detection
regardless of breast density. Cheng et al presented similar
results in a prevalent round in an Asian population.28
Quality of Screening
BI-RADS Benchmarks
Despite the excellent results of breast MRI screening reported
above, it is imperative to realize that all screening comes at a
cost, and that the balance between risks to women without
breast cancer and benefits for women with breast cancer must
be observed.
To this end the BI-RADS lexicon incorporates perfor-
mance benchmarks for breast MRI screening that are listed in
Table 4.94 Based on the reported performance in the studies
described above, achievable performance measures are also listed.
In direct comparison, a large study by Lee et al showed that
most of the BI-RADS benchmarks were easily reached.35 Strigel
et al only reported a higher incidence of node-positive invasive
cancers, albeit this was a much smaller study.95 Vreemann et al
showed that performance of screening is highly dependent on
the actual screening indication.27 For example, the sensitivity of
the screening program was only 81% in BRCA1 carriers,
whereas it exceeded 90% for all other indications, which is likely
an effect of the fast growth of cancers in these women. Recently,
Guindalini et al showed that with a biannual breast MRI screen-
ing protocol, the frequency of interval cancers in this group was
0.96 On the other hand, Vreemann et al27 reported a positive
predictive value for biopsy of only 14% in women with a posi-
tive family history as the only risk factor, whereas it was around
30% for most other indications, which is due to the lower prev-
alence of cancer in the familial risk group. This implies that it is
of paramount importance to be aware of the screening indica-
tion and adjust recall and biopsy thresholds depending on the
degree of individual risk.
The suggested CDR of MRI screening for the estab-
lished indications is between 20 and 30 per 1000. However,
this figure depends heavily on the subgroup screened and the
screening round. While in first-round examinations between
15 and 30 cancers can likely be found in most populations,
in follow-up rounds the CDR should return to (or just above)
the baseline frequency of cancer detection in that population.
In other words, for women at average risk the CDR on
follow-up examinations should not exceed 3–4/1000 for
annual or about 7/1000 for biennial screening. Consequently,
in longitudinal screening programs that include women at
risks lower than that of BRCA mutation carriers, the BI-
RADS benchmark cannot be met.
False-Negative Examinations
Unfortunately, not all cancers are detected by MRI screening.
While some are not visible, a large fraction of undiagnosed
cancers is due to reading or management errors, which may
be caused by lack of experience in the detection of more sub-
tle abnormalities,97 but are likely always present. Pages et al
retrospectively reviewed the priors of 60 MRI screen detected
breast cancers, reporting that 28 of these lesions would be
regarded as BI-RADS 3–5 lesions in the prior, six lesions had
been missed, 15 lesions were misdiagnosed, and seven lesions
were mismanaged due to incorrect tissue sampling at second-
look ultrasound.98 In a similar study, Yamaguchi et al
reported that 7 out of 15 cancers were retrospectively visi-
ble.99 In a recent study of 131 cancers with priors, including
TABLE 4. BI-RADS Benchmarks and Achievable
Performance Levels for MRI-Based Screening
Indicator
BI-RADS
benchmark Achievable
Cancer detection
rate (1000
examinations)
20–30 Depends on screening
indication
and screening round
(prevalent vs
incident)
PPV2 (%) 15 20
PPV3 (%) 20–50 25-40
Sensitivity (%) >80 >90 (except in
BRCA1)
Specificity (%) 85–90 90 (first round), >95
(follow-up)
Minimal
cancera (%)
>50 >70
Node negative
cancer
>80 >80
aMinimal cancer is defined as invasive cancer with size <1 cm or
DCIS. PPV2 = positive predictive value for women referred to
biopsy. PPV3 = positive predictive value for women who
underwent biopsy.
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16 interval cancers, Vreemann et al reported that overall 34%
of cancers were actionable on the prior scan.100 The presence
of a BRCA mutation largely reduced the risk on false-negative
examinations, which reflects the lower threshold for work-up
in these women. Less than perfect image quality increased the
risk. In order to preserve the balance between detection and
prevention of harm to women without cancer, such errors are
likely unavoidable, albeit their frequency can possibly be
reduced by incorporating double-reading or computer-aided
diagnosis. Regardless, auditing of MRI screening on a regular
basis, as is also common for mammography screening, seems
advisable.
Cost-Effectiveness of MRI Screening
The relatively slow adoption of breast MRI as a screening
modality of choice is partly due to the limited availability of
MRI scanners. However, more important, its use is forestalled
by the high costs of the examination. For BRCA mutation car-
riers, estimates vary widely, but studies in general conclude that
breast MRI screening is cost-effective at a willingness to pay
$100,000 per quality adjusted life year gained.101–105 How-
ever, for women at lower risks most studies show that breast
MRI is likely not cost-effective at this level.103,106,107 Saadat-
mand et al showed that the younger you start with MRI
screening in women with a familial risk, the less cost-effective
it becomes due to the lower frequency of cancers in younger
women.107 Despite the fact that these studies are based on the
initial MRI studies, in which MRI performance was lower,
many European breast cancer guidelines deviate from the ACS
recommendations by excluding women without a very strong
familial risk.6,108 There are two major drivers for cost-effective-
ness: the frequency of undiagnosed breast cancer, and the cost
of the MRI scan itself.102,103 For women at average risk, the
frequency of breast cancer is relatively low, and therefore the
number of screens needed to detect a breast cancer is relatively
high, which implies that at the current cost of breast MRI,
MRI screening in this population is very unlikely to be cost-
effective. However, considering the smaller average tumor size,
and the propensity of breast MRI to preferentially detect the
more aggressive breast cancer subtypes,31 adjustment of the
screening interval (making it longer) may be considered to
improve the cost-effectiveness.
Future Perspectives
To enable wider use of breast MRI and improve cost-effec-
tiveness, the use of shorter and less costly MRI protocols is
mandatory. The concept of abbreviated breast MRI was
introduced to enable this,109,110 reducing the acquisition time
to 3 minutes and making reading much faster. Many studies
evaluating this concept have been published in recent years,
showing that abbreviated protocols provide virtually equal
cancer detection performance compared with more extended
multiparametric protocols.111 Ultrafast dynamic sequences,
with a temporal resolution that is typically below 5 seconds,
obtained during contrast inflow can be used to preserve speci-
ficity, without penalty in acquisition time.112,113 Evaluating
only these ultrafast acquisitions was recently shown to yield
similar results as reading a full diagnostic protocol, including
the late phase of enhancement, T2, and diffusion-weighted
imaging (DWI).114 Unfortunately, breast MRI still relies on
the administration of an intravenous contrast agent. This is
time-consuming, costly, painful, and has the potential for
complications, despite the fact that the currently used macro-
cyclic contrast agents are very stable and safe.115 MRI tech-
niques that do not rely on contrast administration such as
DWI are therefore under evaluation. Studies have so far been
unequivocally successful in showing that DWI is at least as
sensitive as mammography for the early detection of
cancer.116–118 Recent advances, such as the use of readout
segmented DWI and reduced field of view DWI, have
improved image quality,119–122 whereas the use of strong
background suppression and higher b-values have been shown
to improve lesion visibility.118,123 However, the limited spa-
tial resolution and the frequent presence of artifacts reduces
the value of DWI in the detection of lesions smaller than
12 mm.124 Consequently, at this point in time MRI tech-
niques without intravenous contrast administration cannot
compete with contrast-enhanced breast MRI for screening
purposes. Recently, the Journal of Magnetic Resonance Imaging
published a large review on abbreviated, ultrafast, and
noncontrast-enhanced MRI that summarizes the existing
studies.111 For a more detailed description of these tech-
niques, which are believed to be important to enable the use
of breast MRI in a larger population, the reader is referred to
this publication.
Conclusion
The current literature clearly shows that, for early breast can-
cer detection, contrast-enhanced breast MRI outperforms
noncontrast-based alternatives such as mammography and
ultrasound in all women at increased risk for breast cancer
development, and probably also for women at average risk.
The supplemental use of mammography may slightly increase
cancer detection over breast MRI alone, but also reduces
specificity. Supplemental use of ultrasound only decreases
specificity and should be avoided. The earlier detection of
cancers with MRI seems to translate into survival benefits in
women who participated in the initial MRI screening studies,
which is fully in line with the concept of screening for breast
cancer and will therefore likely hold true for all indications. A
point of concern is that MRI has a higher sensitivity for all
types of breast cancer, including low-grade DCIS, and may
therefore also increase overdiagnosis. While indications for
breast MRI screening are expanding, its wider use is mainly
386 Volume 50, No. 2
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stalled by the limited availability of MRI scanners and high
costs of the examination, along with the need for contrast
administration. Abbreviated breast MRI protocols may allevi-
ate these issues, but the use of intravenous contrast agents is
still mandatory.
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